´ø×´ðåÕîÊÇÓɳ¤ÆÚDZ·üÔÚ¼¹Ëèºó¸ùÉñ¾½Ú»òÂÉñ¾½ÚÄÚµÄË®¶»-´ø×´ðåÕ¶¾£¨varicella-zoster virus£¬VZV£©¾ÔÙ¼¤»îÒýÆðµÄ¸ÐȾÐÔƤ·ô²¡[1]¡£¸Ã²¡³ýƤ·ôËðº¦Í⣬ÍùÍù°éÓÐÉñ¾²¡ÀíÐÔÌÛÍ´£¬³£³öÏÖÔÚÄêÁä½Ï´ó¡¢ÃâÒßÒÖÖÆ»òÃâÒßȱÏݵÄÈËȺÖУ¬ÑÏÖØÓ°Ï컼ÕßÉú»îÖÊÁ¿£¬Òò´ËÒ²ÊÇÉñ¾ÄڿƵij£¼û²¡¡£
´ø×´ðåÕîºóÒÅÉñ¾Í´£¨postherpetic neuralgia£¬ PHN£©ÊÇ×î³£¼ûµÄ´ø×´ðåÕîÂýÐÔ²¢·¢Ö¢£¬Ò²ÊÇ×î³£¼ûµÄ¸ÐȾºóÉñ¾Í´ÀàÐÍ¡£Í¨³£½«PHN¶¨ÒåΪƤÕî³öÏÖºóÖÁÉÙ³ÖÐø1¸öÔ»ò3¸öÔ¡¢6¸öÔµÄÌÛÍ´¡£µ«Ä¿Ç°¹ú¼ÊÉÏÉÐδ´ï³É¹²Ê¶£¬¹úÍâ×î³£ÓõĶ¨Òå¼´´ø×´ðåÕîƤÕî³öÏÖºóÖÁÉÙ³ÖÐø3¸öÔµÄÌÛÍ´[2]¡£ÎÒ¹ú¡¶´ø×´ðåÕîºóÉñ¾Í´Öйúר¼ÒÕïÁƹ²Ê¶¡·Ã÷È·Ö¸³ö£¬PHNÊÇƤÕîÓúºÏºó³ÖÐø1¸öÔ¼°ÒÔÉϵÄÌÛÍ´[3]¡£
PHN·¢²¡ÂÊÕ¼´ø×´ðåÕÕßµÄ5% ~ 30%£¬ÎÒ¹úÔ¼ÓÐ400ÍòPHN»¼Õß¡£PHN¶à¼ûÓÚ¸ßÁä¡¢ÃâÒß¹¦ÄܵÍÏ»¼Õߣ¬ÌÛÍ´²¿Î»Í¨³£±ÈðåÕîÇøÓòÓÐËùÀ©´ó£¬³£¼ûÓÚµ¥²àÐز¿¡¢Èý²æÉñ¾»ò¾±²¿¡£ÌÛÍ´ÐÔÖʶàÑù£¬¿ÉΪÉÕ×ÆÑù¡¢µç»÷Ñù¡¢µ¶¸îÑù¡¢Õë´ÌÑù»ò˺ÁÑÑù¡£Ò»ÖÖÌÛʹΪÖ÷£¬»ò¶àÑùÌÛÍ´²¢´æ¡£Ã÷ÏÔÈÅÂÒ»¼ÕßµÄ˯Ãß¡¢ÇéÐ÷£¬Ó°Ï칤×÷ºÍÈÕ³£Éú»î£¬ÑÏÖؿɵ¼Ö¾«ÉñÕÏ°ºÍÒÖÓô¡£30% ~ 50%µÄ»¼ÕßÌÛÍ´³ÖÐø³¬¹ý1Ä꣬²¿·Ö²¡³Ì¿É´ï10Äê»ò¸ü³¤[1]¡£
ÄÇô£¬PHNÄܳ¹µ×ÖÎÓúô£¿ÈçºÎÕë¶Ô²»Í¬½×¶ÎµÄ»¼Õß½øÐÐÖÎÁÆ£¿
×ܵÄÀ´Ëµ£¬PHNÖÎÁÆÓ¦ÁªºÏÖÎÁÆ¡¢×ÛºÏÖÎÁÆ£¬ÐèÒªÆÀ¹ÀÁÆЧÓ밲ȫÐÔ·çÏÕ£¬Í¬Ê±ÒÔÏà¶ÔС¼ÁÁ¿¿ªÊ¼¡¢Öð½¥Ôö¼Ó¼ÁÁ¿ÎªÔÔò¡£´ËÍ⣬ÖÎÁÆÄ¿µÄÊǸÄÉÆÌÛÍ´¡¢¸ÄÉÆ˯Ãß¡¢Ìá¸ßÉú»îÖÊÁ¿¡£¸ù¾Ý¡¶´ø×´ðåÕîÖйúר¼Ò¹²Ê¶¡·£¨2018 Ä꣩[1]£¬Ôڴ˽¨Ò飺
1.ÍâÓÃÒ©Îï
ÒÔ¸ÉÔï¡¢ÏûÑ×ΪÖ÷¡£ðåҺδÆÆʱ¿ÉÍâÓï¸Êʯϴ¼Á¡¢°¢ÎôÂåΤÈé¸à»òÅçÎôÂåΤÈé¸à£»ðåÕîÆÆÀ£ºó¿É×ÃÇéÓÃ3%ÅðËáÈÜÒº»ò1¡Ã5 000ß»à«Î÷ÁÖÈÜҺʪ·ó£¬»òÍâÓÃ0.5%ÐÂùËØÈí¸à»ò2%ĪƥÂÞÐÇÈí¸àµÈ¡£ÑÛ²¿¿ÉÍâÓÃ3%°¢ÎôÂåΤÑ۸ࡢµâÜÕ£¨ðåÕî¾»£©µÎÑÛÒº£¬½ûÓÃÌÇƤÖʼ¤ËØÍâÓÃÖƼÁ¡£
2.Ò©ÎïÖÎÁÆ
¶ÔÓÚÇáÖжÈÌÛÍ´£¬¿¼ÂÇ´¦·½¶ÔÒÒõ£°±»ù·Ó¡¢·ÇçÞÌåÀ࿹Ñ×Ò©»òÇúÂí¶à£»ÖÐÖضÈÌÛʹʹÓð¢Æ¬ÀàÒ©ÎÈçÂð·È»òôÇ¿¼Íª£¬»òÖÎÁÆÉñ¾²¡ÀíÐÔÌÛÍ´µÄÒ©ÎÈç¸ÆÀë×ÓͨµÀµ÷½Ú¼Á¼Ó°ÍÅ綡¡¢ÆÕÈð°ÍÁֵȣ¨¸ÃÀàÒ©Îï¾ßÌåÓ÷¨Èç±í1£©¡£
ÆäÖУ¬´ø×´ðåÕîÆÚ¼äÖضȼ±ÐÔÌÛÍ´ÊÇ·¢ÉúPHNµÄΣÏÕÒòËØ£¬ÁªºÏ¸ÆÀë×ÓͨµÀµ÷½Ú¼Á²»½öÄÜÓÐЧ»º½âÌÛÍ´£¬¶øÇÒÄܼõÉÙPHN·¢Éú¡£Ñо¿ÏÔʾ£¬ÔçÆÚʹÓÃÆÕÈð°ÍÁÖ¿ÉÏÔÖø½µµÍ´ø×´ðåÕîÆÚÌÛÍ´ÆÀ·Ö£¬ÓÈÆäÔÚðåÕî·¢Éú7 dÄÚʹÓÃÄÜÏÔÖø½µµÍPHN·¢ÉúÂÊ¡£
´ËÍ⣬ÆÕÈð°ÍÁÖÁªºÏôÇ¿¼Íª²»½öÄܽøÒ»²½½µµÍPHN·¢ÉúÂÊ£¬»¹¿É¸ÄÉÆ»¼ÕßÈÕ³£»î¶¯Óë˯Ãߣ¬Ìá¸ßÉú»îÖÊÁ¿¡£³ýÍâÉÏÊöÈý»·À࿹ÒÖÓôÒ©ÎTCAs£©Èç°¢Ã×ÌæÁÖ£¬Ñо¿±íÃ÷£¬5-ôÇÉ«°·ºÍÈ¥¼×ÉöÉÏÏÙËØÔÙÉãÈ¡ÒÖÖƼÁ£¨SNRIs£©ÈçÎÄÀ·¨ÐÁ¡¢¶ÈÂåÎ÷Í¡£¬¿ÉÒÖÖÆ 5-ôÇÉ«°·ºÍÈ¥¼×ÉöÉÏÏÙËصÄÔÙÉãÈ¡£¬¿ÉÓÃÓÚÖÎÁÆ PHN£¬ÄܸÄÉÆÂéľÑùÍ´¡¢×ÆÍ´¡¢×¹ÕÍÍ´µÈ£¬Ò²ÄܸÄÉÆÐÄÇéºÍ˯Ãß¡£
ͨ³££¬ÎÄÀ·¨ÐÁÓÐЧ¼ÁÁ¿Îª150-225 mg/d£¬Ã¿ÈÕ1´Î¡£¶ÈÂåÎ÷Í¡µÄ¼ÁÁ¿ÎªÃ¿ÈÕ30-60mg/d£¬Ã¿ÈÕ1-2´Î¡£Ó¦×¢ÒâÁ½Õß³£¼û²»Á¼·´Ó¦ÓжñÐÄ¡¢¿Ú¸É¡¢³öº¹¡¢½¹ÂÇ¡¢·¦Á¦¡¢Õð²ü¡¢Ôö¼Ó³öѪ·çÏյȡ£°üÀ¨ôÇ¿¼ÍªÔÚÄڵݢƬÀàÒ©ÎÂð·È¡¢ôÇ¿¼Íª¡¢·ÒÌ«Äá¡¢ÇúÂí¶àµÈ£©ÊÇÖÎÁÆÖÐÖضÈPHNµÄÊ×Ñ¡Ò©ÎÆä¿ÉÓÐЧÖÎÁÆ PHN µÄÉÕ×ÆÍ´¡¢Õë´ÌÍ´¼°Í´¾õ³¬Ãô£¬Ð¡¼ÁÁ¿¿ªÊ¼£¬ÖÎÁÆÎÞЧӦÁ¢¼´Í£Ò©£¬Ò»°ãʹÓò»³¬¹ý8ÖÜ¡£
ͨ³££¬ÇúÂí¶àÆðʼ¼ÁÁ¿Ã¿´Î25-50 mg¡¢Ã¿ÈÕ1-2 ´Î£¬×î´ó¼ÁÁ¿ 400 mg/d¡£ÒòÆä¿ÉÒýÆðÒ©ÎïÒÀÀµ£¬¹ÊÐèµÍ¼ÁÁ¿¿ªÊ¼¡¢»ºÂýÖð½¥¼ÓÁ¿¡¢Öð²½Í£Ò©¡£´ËÀàÒ©ÎïÖ÷ÒªµÄ²»Á¼·´Ó¦°üÀ¨¶ñÐÄ¡¢Å»Í¡¢±ãÃØ¡¢Í·ÔΡ¢ÄòäóÁô¡¢ÊÈ˯ºÍÍ·Í´µÈ£¬Óë¼ÁÁ¿Ïà¹Ø¡£²»Óë 5-ôÇÉ«°·Ò©Î°üÀ¨ SNRIs£©Í¬Óã¬ÒÔ±ÜÃâ5-ôÇÉ«°·×ÛºÏÕ÷·çÏÕ¡£
3.ÈçºÎÔ¤·À
ĿǰΨһÓÐÃ÷È·Ö¤¾ÝµÄÔ¤·À´ø×´ðåÕîºóÒÅÉñ¾Í´µÄ·½·¨¾ÍÊÇÔ¤·À´ø×´ðåÕîµÄ·¢Éú¡£ÆäÖУ¬¿¹²¡¶¾Ò©ÎïÖÎÁƼ±ÐÔ´ø×´ðåÕîµÄÈô¸É°²Î¿¼Á¶ÔÕÕÁÙ´²ÊÔÑéÏÔʾ£¬¿¹²¡¶¾Ò©ÎïÄܽµµÍ¼±ÐÔÌÛÍ´µÄÇ¿¶È¡¢¼õÇáðåÕîÖ¢×´¡¢¼ÓËÙðåÕîÏûʧ£¬²¢ÇÒÄÜËõ¶ÌÌÛÍ´³ÖÐøʱ¼ä¡£
´ËÍ⣬ÓÐÑо¿ÏÔʾ£¬Ò»ÖÖ´ø×´ðåÕîÒßÃçZostavaxÔ¤·À60ËêÒÔÉÏÈËȺ·¢ÉúPHNµÄÓÐЧÂÊΪ66.5%[4]¡£
×ÛÉÏ£¬PHNÊÇÒ»¸ö¿É·À¿ÉÖεļ²²¡£¬ÔçÆÚ¼°Ê±¿¹²¡¶¾ÖÎÁÆÊÇÔ¤·ÀPHNÌÛÍ´³Ì¶È¼ÓÖصĿɿ¿·½·¨¡£Ñ¡ÓúÏÊʵÄÒ©ÎïÖÎÁÆ¿ÉÓÐЧ½µµÍPHN·¢Éú£¬»¹¿É¸ÄÉÆ»¼ÕßÈÕ³£»î¶¯Óë˯Ãߣ¬Ìá¸ßÉú»îÖÊÁ¿¡£
²Î¿¼ÎÄÏ×£º
[1]´ø×´ðåÕîÖйúר¼Ò¹²Ê¶[J].ÖлªÆ¤·ô¿ÆÔÓÖ¾£¬2018£¬51(6)£º403-406
[2] Pr¨¦audE£¬UhartM£¬B?hmK£¬ et al. Cost-effectiveness analysis of a vaccination program for the prevention of herpes zoster and post-herpetic neuralgia in adults aged 50 and over in Germany[J]. Hum Vaccin Immunother£¬ 2015£¬11£¨4£©£º884-896. doi£º 10.1080/21645515.2015.1011561.
[3]´ø×´ðåÕîºóÉñ¾Í´ÕïÁƹ²Ê¶±àдר¼Ò×é.´ø×´ðåÕîºóÉñ¾Í´ÕïÁÆÖйúר¼Ò¹²Ê¶[J].ÖйúÌÛʹҽѧÔÓÖ¾£¬ 2016£¬22£¨3£©£º161-167. doi£º 10.3969/j.issn.1006-9852.2016.03.001.
[4] PellissierJM£¬BrissonM£¬LevinMJ. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults[J]. Vaccine£¬2007£¬25£¨49£©£º8326-8337. doi£º 10.1016/j.vaccine.2007.09.066.
williamhill ÖÐÎÄ (www.box4s.com)ר¸å£¬Î´¾ÊéÃæÊÚȨÇëÎðתÔØ¡£
³ÉÈ˲¿·ÖÐÔñ²ðï·¢×÷µÄÌí¼ÓÖÎÁÆ¡£[Ïêϸ]
È¥¿´¿´ £¤90.67ÓÃÓÚÖÎÁÆË®¶»´ø×´ðåÕî¼°¢ñÐÍ¡¢¢òÐ͵¥´¿ðåÕîµÄ¸ÐȾ£¬°üÀ¨³õ·¢ºÍ¸´·¢µÄÉúÖ³Æ÷ðåÕî¡£±¾Æ·ÔÚÒ½ÉúµÄÖ¸µ¼Ï£¬¿ÉÓÃÓÚ°¢ÎôÂåΤµÄËùÓÐÊÊÓ¦Ö¢¡£[Ïêϸ]
È¥¿´¿´ £¤22.94ÓÃÓÚÖÎÁÆË®¶»´ø×´ðåÕî¼°IÐÍ¡¢IIÐ͵¥´¿ðåÕ¶¾¸ÐȾ£¬°üÀ¨³õ·¢ºÍ¸´·¢µÄÉúÖ³Æ÷ðåÕ¶¾¸ÐȾ¡£±¾Æ·¿ÉÓÃÓÚ°¢ÎôÂåΤµÄËùÓÐÊÊÓ¦Ö¢¡£[Ïêϸ]
È¥¿´¿´ £¤7.9Éó¤ÁìÓò£º°×ñ°·ç¡¢Æ¤·ôÃÀÈÝ¡¢Å£Æ¤Ñ¢¡¢ÍÑ·¢¡¢Ý¡ÂéÕʪÕîµÈ¸÷ÖÖƤ·ô²¡¡£
Éó¤ÁìÓò£ºÊªÕƤÑ׵ȹýÃôÐÔƤ·ô²¡£¬¹â»¯Ñ§ÁÆ·¨ÖÎÁÆÒøм²¡
Éó¤ÁìÓò£ºÍç¹ÌÐÍ¡¢´óÃæ»ý¡¢¾ÃÖβ»Óú°×ñ²·ç¡¢Òøм²¡¡¢×ù´¯¡¢ÊªÕîÀà³£¼û²¡¼°¸÷ÖÖƤ·ô¼²²¡µÄÕïÖΡ£